Method of enhancing the immunotherapeutic activity of immune cells by depletion of CD8.sup.+ T cells
US5641677A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 10, 1994 |
| Grant date | Jun 24, 1997 |
| Priority date | — |
| Expiry date | Aug 10, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/515
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for enhancing the immunotherapeutic activity, e.g., cytotoxicity, of immune cells by depleting immune cells of a cell subset that down-regulates the immune response, such as either CD4.sup.+ or CD8.sup.+ lymphocytes. The remaining depleted immune cells are then cultured in the presence of interleukin-2 (IL-2) and an antibody to a lymphocyte surface receptor, preferably an anti-CD3 monoclonal antibody (MoAb). The present invention also provides a method of enhancing the immunotherapeutic activity, e.g., cytotoxicity, of immune cells by culturing immune cells in the presence of IL-2 and an antibody to a lymphocyte surface receptor, preferably an anti-CD3 MoAb; separating a cell subset capable of developing immunotherapeutic activity, e.g., cytotoxicity, from the cultured immune cells, e.g., either CD4.sup.+ or CD8.sup.+ lymphocytes; and then subculturing the separated lymphocytes in the presence of IL-2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.